

# Time matters – Die Rolle der Expositionszeit bei der Beurteilung des Risikos von Arzneimitteltherapien in der Schwangerschaft

Reinhard Meister

Beuth Hochschule für Technik, Berlin

# Agenda


Towards demonstration of **time specific** effects of discontinued exposure:

- Pregnancy outcome – basics
- The German embryotox cohort
- Analyses for permanent and for time-dependent exposure
- Modeling non-continuous exposure
- Summary



# Pregnancy – not without risk

Data DESTATIS(2011)



*each of the 180 squares represents 5.000 pregnancies*

662.685 live births, thereof 25.000 with birth defects  $\approx 3-5\%$

108.915 induced abortions


130.000 spontaneous abortions  $\approx 15-16\%$

900.000 total



# Pregnancy – not without risk

Data DESTATIS(2014)



*each of the 190 squares represents 5.000 pregnancies*

714.900 live births, thereof 27.500 with birth defects  $\approx$  3-5%

99.715 induced abortions

135.000 spontaneous abortions  $\approx$  15-16%

950.000 total



# The German Embryotox Cohort

[www.embryotox.de](http://www.embryotox.de) – background and facts

- The Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy works since 1988. Founding member of ENTIS.
- Provides counselling on drug risks in pregnancy and lactation by highly qualified medical/pharmaceutical academics.
- Runs a database (> 40.000 completed cases) of pregnancy outcome with prospectively ascertained information on anamnestic features, exposure information etc. sampled before outcome of pregnancy is known.
- Performs studies according to good practice for clinical epidemiology.
- The internet platform is a link to statistics in practice, giving independent information on drug risks for > 400 common medicinal products. (currently 6000-8000 visitors/day)

Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome - Methodological considerations. *Reprod Toxicol* 2008; 26: 36-41.



# Communicating risk – counselling and online information

Embryotox - Arzneimittelsicherheit in Schwangerschaft und Stillzeit: Einführung

[www.embryotox.de](http://www.embryotox.de)

Arzneimittelsicherheit in Schwangerschaft und Stillzeit

[Embryotox](#) [Hinweise](#) [Fragebögen](#) [Medikamente](#) [Erkrankungen](#)  
[Frauen und Psyche](#)

Embryotox



[▼ Einführung](#) [▶ Aktuelles](#) [▶ Veröffentlichungen](#) [▶ Aktuelle Studien](#) [▶ Kontakt/Impressum](#)



Wir befolgen den  
HONcode Standard  
für vertrauenswürdige

Gesundheitsinformationen.  
Überprüfen Sie dies hier.

CHARITÉ


UNIVERSITÄTSMEDIZIN BERLIN

**ACHTUNG: WIR SIND UMGEZOGEN, NEUE FAX-Nr  
030/450-525902 UND NEUE TELEFONNUMMER - SIEHE  
☞ [Kontakt/Impressum](#)**

Guten Tag,  
Sie befinden sich auf der Informationsseite des  
Pharmakovigilanz\*- und Beratungszentrums für  
Embryonaltoxikologie. Als öffentlich gefördertes, unabhängiges  
Institut bieten wir ☞ **seit 1988 Ärztinnen und Ärzten** sowie  
anderen im Gesundheitswesen Engagierten unabhängige  
Informationen zur Verträglichkeit der wichtigsten Medikamente



# Pregnancy Outcome – competing risks



States and transitions in a multistate description of pregnancy outcome.

The rates  $\alpha_k(t)$  are the *driving forces*. Cumulative incidence for a certain final state may be influenced by transitions to competing states. The functions  $F_k(t)$  are called cumulative incidences. In this paper we concentrate on  $F_2$ :

spontaneous abortion.



# Estimation and Inference – one sample case

- data  
event time  $T$  and an event type  $k = 1, \dots, K$
- cumulative incidence functions  
 $F_k(t) := P(T \leq t, \text{cause} = k)$
- marginal distribution function  
 $P(T \leq t) = 1 - S(t) = \sum_k F_k(t)$
- estimation based on data in the **risk set** ( $\rightarrow$  left truncation)  
 $\widehat{F}_k(t) = \sum_{i|t'_i \leq t} \widehat{\alpha}_k(t'_i) \widehat{S}(t'_i -), \alpha_k(t)$  cause specific hazard  
 $S(t)$  all cause survival

Computations see **R** package `etm`

Meister R, Schaefer C. Statistical methods for estimating the probability of spontaneous abortion in observational studies. – Analyzing pregnancies exposed to coumarin derivatives. *Reprod Toxicol* 2008; 26: 31-35.

Allignol A, Schumacher M, Beyersmann J. Empirical Transition Matrix of Multistate Models: The `etm` Package. *Journal of Statistical Software*. 2011;38(4):1–15.


Beyersmann, J., Allignol, A., and Schumacher, M. (2012). *Competing Risks and Multistate Models with R*. Springer, New York.





# Pregnancy Outcome – competing risks and left truncation

## Avoid length bias



Wacker E, Navarro A, Meister R, Padberg S, Weber-Schoendorfer C, Schaefer C. Does the average drug exposure in pregnant women affect pregnancy outcome? A comparison of two approaches to estimate the baseline risks of adverse pregnancy outcome. *Pharmacoepidemiology and drug safety* (2015)



# Embryotoxic Effects – principles

## Paracelsus (1538) Septem Defensiones



*Wenn ihr jedes Gift recht auslegen wollt, was ist, das nit Gift ist? Alle Dinge sind Gift, und nichts ist ohne Gift; allein die dosis machts, daß ein Ding kein Gift sei.* (Wiki)

Embryotoxicity is special!

## Paracelsus paradigm update – The Thalidomide tragedy


- Dose is not the sole determinant of toxicity.
- Susceptibility varies with **gestational age**.
- There are organ-specific critical periods for **birth defects** in humans Lenz (1962), Nowak (1965) ( $n = 88$  cases).

In pregnancy, susceptibility for certain effects is not constant, due to embryonic development and changes in maternal conditions.



# A-(H1N1)v2009 Vaccination – change of exposure

Avoid time dependent bias




No increased risk for spontaneous abortion after vaccination observed. Analysis using a cause specific Cox-model, with vaccination as time-dependent covariate.


Oppermann M, Fritzsche J, Weber-Schoendorfer C, Keller-Stanislawski B, Allignol A, Meister R, Schaefer C. A-(H1N1)v 2009: A controlled observational prospective cohort study on vaccine safety in pregnancy. *Vaccine* 2012; 30: 4445-52.

# Non Continuous Exposure – a multistate approach

Multiple final states (competing risks)  
transient exposure states



*continuous exposure*




*single application*

$C$ : no exposure, control     $E$ : exposed     $D$ : exposure discontinued  
 $F_k$ : final state     $k$  = induced abortion, spontaneous abortion, birth



# Discontinued Exposure – new data on anti-coagulants



Cause specific Cox model  
time dependent discontinuation  $d(t)$

start	stop	state	$d(t)$
$t_{entry}$	$t_d$	cens	0
$t_d$	$t_{exit}$	$O(t_{exit})$	1


Counting process notation of time dependent covariates  $n=414$ .

HR\* (95% CI): 1.62(0.65, 4.05)  
\*: reciprocal


```
fit.d <-coxph(Surv(start,stop,state==2)~ d,data=counting)
```



# Discontinued Exposure – exposure and transitions




Marginal frequencies in exposure, transitions, and final states.



- majority of pregnant women enter the study after discontinuation
- joint Cox model with discontinuation time not feasible  
(no conditioning on the future)



# Discontinued Exposure – discontinuation time



Cause specific Cox model using discontinuation time  $t(d)$

start	stop	state	$t(d)$	$d(t)$
$t_{entry}$	$t_{exit}$	$O(t_{exit})$	$t_d$	1

Only observations with discontinued exposure used  $n=403$

HR (95% CI): 1.14(1.02, 1.27)

```
fit.td <-coxph(Surv(start,stop,state==2)~ t.d,  
              data=subset(counting,d==1))
```



# Time Dependent vs Time Specific – first experiences

Anticoagulants (n=414) and low dose MTX (n=197)

	time-dependent			time-specific		
	HR	95% CI		HR	95% CI	
Coumarin	1.62	0.65	4.05	1.14	1.02	1.27
Methotrexate	3.86	1.52	9.83	0.99	0.81	1.21

*Spontaneous Abortion: results varying between substances*

	time-dependent			time-specific		
	HR	95% CI		HR	95% CI	
Coumarin	2.62	1.12	6.01	1.39	1.25	1.54
Methotrexate	0.64	0.08	4.91	1.33	1.20	1.46

*Elective Termination: interpretation to be done*

Weber-Schoendorfer et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. (2014)





## Results and points to consider

- Event-history methods allow bias-reduced estimation of spontaneous abortion rates when accounting for left-truncation and competing risks.
- Length bias and time-dependent bias can be reduced (**removed?**).
- Estimation of time-specific effects of exposure state is **feasible** within the proportional hazard framework.
- Communication of results and problems has to be **addressed**.
- **Caveat!** Tacitly non-informative left-truncation is assumed.
- **Caveat!** Informative left-truncation – can adjustment reduce effects?
- **Caveat!** What is the rôle of competing outcomes?
- Alternatives to Cox regression – regression of pseudo residuals?



# Acknowledgement

We thank

Maria Hoeltzenbein, Stefanie Padberg, Evelin Wacker (all Charité Berlin), and Martin Schumacher (Univ. Freiburg) for hints on time-specificity, their encouragement and very helpful discussion of our approach.



# References

Wacker E, Navarro A, Meister R, Padberg S, Weber-Schoendorfer C, Schaefer C. Does the average drug exposure in pregnant women affect pregnancy outcome? A comparison of two approaches to estimate the baseline risks of adverse pregnancy outcome. *Pharmacoepidemiology and drug safety* (2015)

Meister R, Schaefer C. Statistical methods for estimating the probability of spontaneous abortion in observational studies. – Analyzing pregnancies exposed to coumarin derivatives. *Reprod Toxicol* 2008; 26: 31-35.

Allignol A, Schumacher M, Beyersmann J. Empirical Transition Matrix of Multistate Models: The etm Package. *Journal of Statistical Software*. 2011;38(4):1–15.

Beyersmann J, Allignol A, and Schumacher M. (2012). *Competing Risks and Multistate Models with R*. Springer, New York.

Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome - Methodological considerations. *Reprod Toxicol* 2008; 26: 36-41.

Lenz W, Knapp K. Die Thalidomid-Embryopathie. *Deutsche Medizinische Wochenschrift* 1962; 87(24): 1232–42

Nowack E. Die sensible Phase bei der Thalidomid-embryopathie. *Humangenetik* 1965; 1(6):516-36

Oppermann M, Fritzsche J, Weber-Schoendorfer C, Keller-Stanislawski B, Allignol A, Meister R, Schaefer C. A-(H1N1)v 2009: A controlled observational prospective cohort study on vaccine safety in pregnancy. *Vaccine* 2012; 30: 4445-52.